Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price target decreased by Bank of America from $61.00 to $47.00 ...

According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price ...

On Friday, Apellis Pharmaceuticals Inc (APLS) stock saw a modest uptick, ending the day at $27.98 which represents a slight increase of $0.72 or 2.64% from the prior close of $27.26. The stock opened ...

In late-session trading, investors were selling out of Apellis, to the point where its price was down by nearly 6%. By ...

The market expects Apellis Pharmaceuticals, Inc. (APLS) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This ...

RBC Capital Mkts has recently initiated Apellis Pharmaceuticals Inc (APLS) stock to Sector Perform rating, as announced on October 25, 2024, according to Finviz. Earlier, on October 16, 2024, William ...

J.P. Morgan analyst Anupam Rama has maintained their bullish stance on APLS stock, giving a Buy rating on October 31. Anupam Rama has given his Buy rating due to a combination of factors including ...

Q3 2024 Earnings Call Transcript November 5, 2024 Apellis Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.46 EPS, expectations were $-0.32. Operator: Good morning, ladies ...

Stifel Nicolaus analyst Annabel Samimy has maintained their bullish stance on APLS stock, giving a Buy rating today. Annabel Samimy’s rating is based on Apellis Pharmaceuticals’ strategic ...

Check the time stamp on this data. Updated AI-Generated Signals for Apellis Pharmaceuticals Inc. (APLS) available here: APLS.